Bioverge

Kiersten Stead, Co-Founder and Managing Partner of DCVC Bio discusses her firm’s approach to deep tech investing in biotech and focus on platform technologies. They delve into the intersection of in vivo CAR-T therapy and AI in healthcare, the challenges of developing safe and effective drugs, and the importance of science and team in biotech. The chapter also emphasizes the value of combining data, people, and technology to gain insights.

Professor of Finance, Andrew Lo, discusses the challenges of funding drug development and proposes a Netflix-inspired subscription model to address the crisis. Topics include innovative financing for biomedical innovation, the inspiring story of a life-saving drug, the value of death in biotech funding, challenges in paying for expensive medicines, breaking constraints in the payment system, and the potential of a subscription model for advanced therapies.

Nathan Hunkapiller, Chief Scientific Officer and Co-Founder of Curve Biosciences, sits down with Neil to discuss liquid biopsies, the company’s efforts to expand the use of these blood-based tests to improve the treatment of chronic diseases, and how it is enabling earlier intervention.